Related Experiment Video

Updated: Feb 19, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.6K

Renin angiotensin system deregulation as renal cancer risk factor

Paweł Sobczuk1,2, Cezary Szczylik1, Camillo Porta3,4

  • 1Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland.

Oncology Letters
|November 4, 2017
PubMed

Insights

Renin-angiotensin system inhibitors, like angiotensin-converting enzyme inhibitors (ACEIs), show promise in altering renal cell carcinoma (RCC) incidence and improving patient survival. ACEIs impact cancer pathways and may help manage hypertension in RCC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Research

Background:

  • The renin-angiotensin system (RAS) has underestimated non-cardiovascular roles, including in carcinogenesis.
  • Antihypertensive agents targeting RAS, such as ACE inhibitors (ACEIs) and angiotensin receptor blockers, provide evidence for RAS's broader functions.
  • ACEIs demonstrate potential in altering renal cell carcinoma (RCC) incidence and prolonging patient survival.

Purpose of the Study:

  • To review the effects of ACE and its inhibitors on RCC.
  • To understand the non-cardiovascular effects of RAS inhibitors in cancer treatment.
  • To outline recent evidence on managing hypertension in RCC patients undergoing tyrosine kinase inhibitor therapy.

Main Methods:

  • Review of preclinical and clinical studies on ACEIs and RCC.
  • Analysis of molecular pathways influenced by RAS inhibitors.
  • Examination of patient survival data and effects on RCC cell lines and xenograft models.

Main Results:

  • ACEIs can decrease angiotensin II (Ang-II) production and alter bradykinin or Ang 1-7 levels.
  • Evidence suggests ACEIs may positively impact RCC incidence and patient survival.
  • Captopril, an ACEI, can manage hypertension and offers renoprotective benefits in RCC patients.

Conclusions:

  • The renin-angiotensin system plays a significant role in non-cardiovascular processes, including cancer.
  • ACE inhibitors represent a potential therapeutic strategy in managing renal cell carcinoma.
  • RAS inhibitors offer insights for combined cancer treatments and managing side effects like hypertension in RCC therapy.
Keywords:
ACEIRCCangiotensin converting enzymehypertensionrenal cancer

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.2K

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.5K